• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in Chronic Lymphocytic Leukemia
【24h】

Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in Chronic Lymphocytic Leukemia

机译：高级实践观察预防和管理肿瘤裂解综合征及慢性淋巴细胞白血病中型蛋白酶的视角

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tumor lysis syndrome (TLS) and neutropenia are significant toxicities in the treatment of chronic lymphocytic leukemia (CLL). Both TLS and neutropenia can lead to potentially life-threatening complications for patients with chronic lymphocytic leukemia undergoing antineoplas-tic therapy. This article focuses on diligent risk assessment, prophylaxis, early identification, monitoring, patient education, and prompt intervention for TLS and neutropenia. These are all necessary steps to reduce life-threatening complications. Guidelines are available for risk assessments for both TLS and neutropenia. Once risk is established, prophylaxis and monitoring recommendations can be found in available guidelines. There are no established guidelines or widely used decision-making standards for the treatment of clinical TLS. General management strategies are well documented in the literature, with some degree of customization to each individual patient. If fever occurs in the setting of neutropenia, there are well-established guidelines for management, including guidance on anti-infective agents and use of growth factors. In addition, awareness and proper actions regarding TLS and neutropenia are key to preventing treatment delays, dose reductions, or treatment discontinuation. Adequate planning for TLS and neutropenia is critical to optimize patient outcomes.
机译：肿瘤溶解综合征（TLS）和中性粒细胞减少症是治疗慢性淋巴细胞白血病（CLL）的重要毒性。对于接受抗肿瘤治疗的慢性淋巴细胞白血病患者来说，TLS和中性粒细胞减少都可能导致潜在的危及生命的并发症。本文着重于TLS和中性粒细胞减少症的勤奋风险评估、预防、早期识别、监测、患者教育和及时干预。这些都是减少危及生命的并发症的必要步骤。TLS和中性粒细胞减少症风险评估指南可用。一旦确定了风险，可以在可用的指南中找到预防和监测建议。对于临床TLS的治疗，没有既定的指南或广泛使用的决策标准。文献中详细记录了一般管理策略，并针对每个患者进行了一定程度的定制。如果中性粒细胞减少症患者出现发热，有完善的管理指南，包括抗感染药物和生长因子的使用指南。此外，对TLS和中性粒细胞减少症的认识和适当行动是防止治疗延迟、剂量减少或治疗中断的关键。充分规划TLS和中性粒细胞减少症对于优化患者预后至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号